Sugiyama Y - Search Results

1

Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin.

Sugiyama Y, Kawakishi S, Osawa T. Sugiyama Y, et al. Biochem Pharmacol. 1996 Aug 23;52(4):519-25. doi: 10.1016/0006-2952(96)00302-4. Biochem Pharmacol. 1996. PMID: 8759023

2

Antioxidative activity of tetrahydrocurcuminoids.

Osawa T, Sugiyama Y, Inayoshi M, Kawakishi S. Osawa T, et al. Among authors: sugiyama y. Biosci Biotechnol Biochem. 1995 Sep;59(9):1609-12. doi: 10.1271/bbb.59.1609. Biosci Biotechnol Biochem. 1995. PMID: 8520105 Free article.

3

L-DOPA cyclohexyl ester is a novel stable and potent competitive antagonist against L-DOPA, as compared to L-DOPA methyl ester.

Misu Y, Goshima Y, Miyamae T, Furukawa N, Sugiyama Y, Okumura Y, Shimizu M, Ohshima E, Suzuki F. Misu Y, et al. Among authors: sugiyama y. Jpn J Pharmacol. 1997 Nov;75(3):307-9. Jpn J Pharmacol. 1997. PMID: 9434265 Free article.

4

Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth.

Igarashi M, Takeda Y, Mori S, Ishibashi N, Komatsu E, Takahashi K, Fuse T, Yamamura M, Kubo K, Sugiyama Y, Saito Y. Igarashi M, et al. Among authors: sugiyama y. Br J Pharmacol. 1997 Mar;120(6):1172-8. doi: 10.1038/sj.bjp.0701018. Br J Pharmacol. 1997. PMID: 9134232 Free PMC article.

5

Inhibitory effects of catechol derivatives on hydrophilic free radical initiator-induced hemolysis and their interaction with hemoglobin.

Kitagawa S, Sugiyama Y, Sakuma T. Kitagawa S, et al. Among authors: sugiyama y. Chem Pharm Bull (Tokyo). 1996 May;44(5):881-4. doi: 10.1248/cpb.44.881. Chem Pharm Bull (Tokyo). 1996. PMID: 8689723

6

L-DOPA cyclohexyl ester is a novel potent and relatively stable competitive antagonist against L-DOPA among several L-DOPA ester compounds.

Furukawa N, Goshima Y, Miyamae T, Sugiyama Y, Shimizu M, Ohshima E, Suzuki F, Arai N, Fujita K, Misu Y. Furukawa N, et al. Among authors: sugiyama y. Jpn J Pharmacol. 2000 Jan;82(1):40-7. doi: 10.1254/jjp.82.40. Jpn J Pharmacol. 2000. PMID: 10874587 Free article.

7

Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.

Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, Abe N, Fukushima K, Matsuura A. Ashizawa N, et al. Among authors: sugiyama y. Jpn J Pharmacol. 1997 Feb;73(2):133-44. doi: 10.1254/jjp.73.133. Jpn J Pharmacol. 1997. PMID: 9074947 Free article.

8

[Studies on novel, stable and potent competitive antagonists against L-DOPA].

Misu Y, Goshima Y, Miyamae T, Furukawa N, Okumura Y, Sugiyama Y, Shimizu M. Misu Y, et al. Among authors: sugiyama y. Nihon Yakurigaku Zasshi. 1997 Oct;110 Suppl 1:159P-164P. doi: 10.1254/fpj.110.supplement_159. Nihon Yakurigaku Zasshi. 1997. PMID: 9503425 Japanese.

9

Effect of trimebutine maleate on the contractile response of the isolated ileum from diabetic rats.

Uchida M, Iwata T, Takagi S, Sugiyama Y, Ishitani K, Honda H, Sakai Y. Uchida M, et al. Among authors: sugiyama y. Gen Pharmacol. 1994 May;25(3):505-8. doi: 10.1016/0306-3623(94)90206-2. Gen Pharmacol. 1994. PMID: 7926598

10

A novel action of collapsin: collapsin-1 increases antero- and retrograde axoplasmic transport independently of growth cone collapse.

Goshima Y, Kawakami T, Hori H, Sugiyama Y, Takasawa S, Hashimoto Y, Kagoshima-Maezono M, Takenaka T, Misu Y, Strittmatter SM. Goshima Y, et al. Among authors: sugiyama y. J Neurobiol. 1997 Sep;33(3):316-28. doi: 10.1002/(sici)1097-4695(199709)33:3<316::aid-neu9>3.0.co;2-4. J Neurobiol. 1997. PMID: 9298768

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,699 results

Search Page

Filters